Debate surrounds the ML tech behind Moderna's cancer vaccine
iskander · x · 2026-08-20
Commenting on the Merck/Moderna cancer vaccine news, the author analyzes the potential machine learning techniques used in their antigen selection process. The discussion speculates on whether they utilized legacy neural networks like netMHCpan or MHCFlurry, or if more advanced post-GPT models were involved. The author emphasizes that clinical success remains significant regardless of whether pre-GPT ML methods were employed.
Related event: AI in Moderna's Cancer Vaccine: Small Models for Neoantigen Selection(2 posts)→
More from Research
- SAI Lab Launches SAI Arena to Evaluate AI Verification Systems — ChenhaoTan · 2026-08-20
- Solving Sim-to-Real challenges with Domain Randomization — ShawnHymel · 2026-08-20
- AI-Driven 'Exercise Pill' Passes Human Trial, Revolutionizing Drug Discovery — TansuYegen · 2026-08-20
- Melanie Mitchell: AI is 'Alien Intelligence' Requiring New Metrics — MelMitchell1 · 2026-08-20
- Humyn Labs: Turning Human Experience into Physical AI Training Data — kimmonismus · 2026-08-20
- OpenMaMMUT Collection: Weights on DataComp and Re-LAION Available — wightmanr · 2026-08-20